We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

110 hedge funds and large institutions have $966M invested in Acceleron Pharma in 2014 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 12

105% more call options, than puts

Call options by funds: $11.8M | Put options by funds: $5.74M

57% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 23

51% more capital invested

Capital invested by funds: $639M → $966M (+$327M)

31% more funds holding

Funds holding: 84 → 110 (+26)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

Holders
110
Holders Change
+26
Holders Change %
+30.95%
% of All Funds
2.93%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
38
Increased
36
Reduced
23
Closed
12
Calls
$11.8M
Puts
$5.74M
Net Calls
+$6.02M
Net Calls Change
+$3.43M

Top Buyers

Rank Fund Capital Flow
1
ORI
Oak Ridge Investments
Illinois
+$21.3M
2
BFA
BlackRock Fund Advisors
California
+$15.2M
3
CCP
Clough Capital Partners
Massachusetts
+$14.4M
4
ICAP
Independence Capital Asset Partners
Colorado
+$11.8M
5
GIM
Granahan Investment Management
Massachusetts
+$10.7M

Top Sellers

Rank Fund Capital Flow
1
QF
QVT Financial
New York
-$8.05M
2
PVMCI
Polaris Venture Management Co IV
Massachusetts
-$7.78M
3
DVC
Deer VII & Co
New York
-$5.29M
4
CAM
Cormorant Asset Management
Massachusetts
-$5.23M
5
PA
Perceptive Advisors
New York
-$4.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$6.42M -$65.1K -1,867 -1%
Brown Advisory
27
Brown Advisory
Maryland
$6.31M +$5.32M +152,616 +1,637%
PAMU
28
Pictet Asset Management (UK)
United Kingdom
$4.53M +$2.46M +70,604 +155%
UBS AM
29
UBS AM
Illinois
$4.42M -$80.2K -2,300 -2%
CS
30
Credit Suisse
Switzerland
$3.91M +$2.58M +74,029 +282%
BG
31
BlackRock Group
United Kingdom
$3.48M +$1.21M +34,675 +63%
Deutsche Bank
32
Deutsche Bank
Germany
$3.37M -$285K -8,180 -9%
WSA
33
Wall Street Associates
California
$3.22M -$17.4K -500 -0.6%
PCM
34
Pentwater Capital Management
Florida
$3.12M +$2.79M +80,000 New
BIM
35
BlackRock Investment Management
Delaware
$2.77M +$491K +14,089 +25%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$2.73M +$82.3K +2,361 +3%
TA
37
Teachers Advisors
New York
$2.71M -$3.48K -100 -0.1%
Geode Capital Management
38
Geode Capital Management
Massachusetts
$2.62M +$68K +1,951 +3%
EAM
39
Eventide Asset Management
Massachusetts
$2.42M – – –
AllianceBernstein
40
AllianceBernstein
Tennessee
$2.37M +$212K +6,093 +11%
TCIM
41
TIAA CREF Investment Management
New York
$2.24M -$97K -2,782 -5%
TD Asset Management
42
TD Asset Management
Ontario, Canada
$2.22M +$52.3K +1,500 +3%
FCMI
43
Foresite Capital Management I
California
$2.17M – – –
CS
44
Candriam SCA
Luxembourg
$2.14M +$1.92M +55,000 New
HP
45
Harbourvest Partners
Massachusetts
$1.99M +$1.78M +51,163 New
HCMT
46
Highland Capital Management (Texas)
Texas
$1.94M +$1.74M +49,800 New
GP
47
GLG Partners
United Kingdom
$1.67M +$1.49M +42,764 New
HLA
48
Hamilton Lane Advisors
Pennsylvania
$1.66M +$1.48M +42,549 New
Principal Financial Group
49
Principal Financial Group
Iowa
$1.59M +$34.9K +1,000 +3%
Charles Schwab
50
Charles Schwab
California
$1.47M +$295K +8,455 +29%
1
2
3 4 5

XLRN Hedge Fund Activity: Q4 2014 in Review

110 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2014, worth a combined $966M — up 51% from $639M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new XLRN positions and 12 closed out — a net gain of 26 holders — while 36 added to existing stakes and 23 trimmed.

The largest buyer was Oak Ridge Investments, adding an estimated $21.3M. The largest seller was QVT Financial, cutting an estimated $8.05M.

  • 110 institutional investors held Acceleron Pharma (XLRN) as of Q4 2014, up from 84 in Q3 2014.
  • Funds reported $966M of Acceleron Pharma stock for Q4 2014, up 51% quarter-over-quarter.
  • 38 funds opened new Acceleron Pharma positions in Q4 2014 and 12 closed out, a net change of +26 holders.
  • The largest Acceleron Pharma buyer in Q4 2014 was Oak Ridge Investments, an estimated $21.3M added.
  • The largest Acceleron Pharma seller in Q4 2014 was QVT Financial, an estimated $8.05M sold.

Based on aggregated 13F filings for Q4 2014.